ArticleJournal of translational medicine2026
Impact of intra-tumoral microbiome on the efficacy of neoadjuvant immunochemotherapy in patients with locally advanced oral squamous cell carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe predictive value of intratumoral microbiota for the efficacy of neoadjuvant immunochemotherapy, as well as the changes in microbiota before and after treatment, has remained largely unexplored.
methodsWe employed 2bRAD sequencing for Microbiome (2bRAD-M) to analyze 42 specimens from patients with locally advanced oral squamous cell carcinoma (OSCC), focusing on trends in intratumoral microbiota changes before and after neoadjuvant immunochemotherapy, and predicting responses to the treatment.
results(1) There was no significant difference between the MPR_before group and nMPR_before group in terms of α diversity and β diversity at baseline, but Ralstonia_sp.000620465, Methylobacterium_rhodesianum, Methylobacterium_jeotgali, RH_AL1_sp.901457705, Rothia_sp.002418375, and Rothia_mucilaginosa_A, which were enriched in immune-related signaling pathways, were significantly more abundant in the nMPR_before group and could predict the efficacy of neoadjuvant immunotherapy (AUC=0.74) . (2) Importantly, both the α and β diversity of intratumoral microbiota significantly decreased after neoadjuvant immunochemotherapy, regardless of whether we compared the MPR_before group with MPR_after group or the nMPR_before group with nMPR_after group. (3) The abundance of Deinococcus_geothermalis was significantly higher in the nMPR_after group, while Burkholderia_vietnamiensis was enriched in the MPR_after group. These differential microbial populations between the nMPR_after group and MPR_after group were enriched in metabolism-related pathways such as carbon fixation in photosynthetic organisms, taurine and hypotaurine metabolism, and genetic information processing pathways, including homologous recombination and DNA replication.
conclusionNeoadjuvant immunochemotherapy markedly alters intratumoral microbiota diversity. Baseline and post-treatment microbiota differences between MPR and nMPR groups implicate specific signaling pathways that may influence treatment efficacy in locally advanced OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.